Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Benzonatate on QT Intervals in Healthy Volunteers
NCT02207699Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2014
- Primary completion
- Jul 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of benzonatate in cough (4 arms), sponsored by Pfizer. Primary endpoint: Fridericia-corrected QTc change from pre-dose to post-dose at 24 hours. Started May 2014; status: completed.
02
Drugs
benzonatate
03
Conditions
cough
Beyond the preview
Go deeper on NCT02207699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207699.